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Radix Angelica sinensis, known as Danggui and mainly spread in Gansu and Sichu-
an provinces of China, has been used for a long time as a traditional Chinese medicine
to treat cardiovascular and cerebrovascular diseases (1, 2) as well as a common food
supplement to reinforce vital energy (3, 4). Modern phytochemical studies have shown
that LIG (Fig. 1) is the main lipophilic component of Danggui (1). Our previous studies
have shown that LIG had neuroprotective effects on some models of diseases associated
with cerebral ischemia. Treatment with LIG could significantly improve behavioral defi-
cits and dose-dependently reduce cerebral infarct volumes after focal cerebral ischemia
in rats (1, 5). It could also prevent chronically hypoperfused cognitive deficits and brain
damage in rats induced by permanent ligation of both common carotid arteries (6). A re-
cent study has shown that LIG has a neuroprotective effect on Alzheimer’s disease, cog-
nitive impairment and neuropathological changes induced by bilateral intracerebroven-
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To improve the stability and oral bioavailability of Z-li-
gustilide (LIG), the inclusion complex of LIG with hyd-
roxypropyl-b-cyclodextrin (HP-b-CD) was prepared by the
kneading method and characterized by UV-Vis spectros-
copy, differential thermal analysis (DTA) and Fourier
transform infrared (FTIR) spectroscopy. LIG is capable of
forming an inclusion complex with HP-b-CD and the stoi-
chiometry of the complex was 1:1. Stability of the inclu-
sion complex against temperature and light was greatly
enhanced compared to that of free LIG. Further, oral bio-
availability of LIG and the inclusion complex in rats were
studied and the plasma drug concentration-time curves
fitted well with the non-compartment model to estimate the
absolute bioavailability, which was 7.5 and 35.9 %, respec-
tively. In conclusion, these results show that LIG/HP-b-CD
complexation can be of great use for increasing the sta-
bility and biological efficacy of LIG.
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tricular injections of Ab25–35 (7). These findings suggest that LIG has the potential to be
developed into a therapeutic agent for preventing and treating ischemic disorders and
Alzheimer’s disease. However, the poor solubility and stability of LIG have strongly in-
fluenced its oral formulation development (8). Therefore, considerable attention has been
paid to increasing the oral bioavailability and physicochemical stability of LIG and de-
veloping its high-quality oral formulation.
In clinical practice, there is a strong argument that oral treatment is essential for chro-
nic diseases of the central nervous system. Oral delivery also improves patients’ compli-
ance and comfort as well as development of chronic treatment schedules, which would
decrease the cost of therapy. Extensive efforts are being focused on resolving the issue of
poor bioavailability of clinically important drugs by employing various pharmaceutical
approaches (9).
Cyclodextrins (CDs) are cyclic oligosaccharides made up of six (a-cyclodextrin),
seven (b-cyclodextrin) and eight (g-cyclodextrin) glucopyranose units linked by a-(1,4)
bonds (10). CDs can interact with appropriately sized molecules to form inclusion com-
plexes. These inclusion complexes have been successfully used to improve the solubility,
stability and bioavailability of many compounds. However, the application of CDs is
limited by their rather low aqueous solubility (11). HP-b-CD is a hydroxyalkyl b-cyclo-
dextrin derivative widely studied in the fields of drug development and food industry
because of its inclusion ability as well as its high water solubility (12, 13). In addition,
toxicological studies have pointed out that HP-b-CD is well tolerated by the human
body both in intravenous and oral administration (12).
More recently, several studies have been performed on the inclusion complexation of
HP-b-CD with natural products such as artemether (14) and astaxanthin (15), but no inclu-
sion complex of LIG with HP-b-CD has been reported to date. In this study, we investigated
the complexation of LIG with HP-b-CD with the aim to improve the bioavailability and sta-
bility of this compound. The complex was prepared by the kneading method at the stoi-
chiometric ratio. UV-Vis spectroscopy, DTA and FTIR spectroscopy were used to charac-
terize the complex. In addition, the stability and oral bioavailability of the LIG/HP-b-CD
inclusion complex in rats were evaluated and compared with that of free LIG.
EXPERIMENTAL
Materials
Danggui was purchased from the Danggui Cultivating Base of Good Agricultural
Practice in Nin Xian County, Gansu Province, China, and LIG was isolated by silica-gel
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Fig. 1. Z-ligustilide structure.
column chromatography, which is a well-established procedure in our laboratory (16).
Its purity was over 97 % based on HPLC analysis. LIG standard substance (98.5 %) was
purchased from J&K Scientific Ltd. (China). HP-b-CD (DS = 6.0) was purchased from
Taixin Yimin Chemical Co. Ltd. (China). All water was distilled and deionized using a
Milli-Q Plus system (Millipore, USA). Acetonitrile (HPLC grade) was purchased from
Fisher Scientific (USA). Other reagents and chemicals were of analytical reagent grade.
UV-Vis spectroscopic studies
UV-visible spectroscopy is an important tool to study complexation of guest mole-
cules with CDs by the shift of absorption maximum and absorbance of these molecules
in the presence of CDs (17). LIG and HP-b-CD were dissolved in a mixed solution of etha-
nol and water (1:1, V/V). A 1.0 mL portion of 3 × 10–4 mol L–1 LIG was transferred accu-
rately into a 10 mL standard flask, 1.0 mL 10–2 mol L–1 HP-b-CD was added sequentially,
diluted to the mark with the same solution and mixed well for 10 min with an ultrasonic
generator. The solution was left to stand for 10 min at room temperature. The UV-Vis ab-
sorption spectra of the LIG/HP-b-CD complex were recorded against a reagent blank
prepared with the same reagent concentration but no LIG. In addition, absorption spec-
tra of LIG and HP-b-CD were recorded according to the same procedure.
Job’s plots
Stoichiometry of the inclusion complex was determined by Job’s method of continu-
ous variation (18). Job’s plot was determined from UV spectrophotometry data accord-
ing to the continuous variation method. LIG and HP-b-CD were dissolved in a mixed
solution of ethanol and water (1:1, V/V). Equimolar 3 × 10–4 mol L–1 solutions of LIG and
HP-b-CD were mixed to a standard volume varying the molar ratio but keeping the total
concentration of the species constant. To calculate stoichiometry, the absorbance at 328
nm was measured for all solutions and the difference in absorbance of LIG (DA) in the
presence and absence of HP-b-CD was plotted against R(R=[LIG]/[LIG]+[HP-b-CD]).
Spectra were obtained with a Shimadzu UV-2450 spectrophotometer (Shimadzu, Japan).
Each complex solution was measured in triplicate.
Preparation of the inclusion complex of LIG with HP-b-CD
An inclusion complex of LIG with HP-b-CD was prepared by the kneading method
(19). LIG and HP-b-CD were weighted precisely in the 1:1 molar ratio on the basis of the
results obtained from Job’s plots studies. Specifically, LIG was dissolved in ethanol.
Drops of LIG solution were added to HP-b-CD, which was wetted with the same solvent
and kneaded thoroughly. During the kneading, drops of ethanol were added to the mix-
ture in order to maintain its consistency as a paste. The obtained solid mixture was then
washed sequentially with water and ethanol. Finally, the mixture was frozen at –80 °C
and subsequently freeze-dried for 24 h at –55 °C using the Labconco Freeze Dry System
(Labconco, USA).
A physical mixture consisting of LIG and HP-b-CD in the same 1:1 molar ratio was
prepared. LIG and the HP-b-CD were added into a mortar and mixed slightly for 5 min
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with a small amount of ethanol (minimum amount to form a slurry) to obtain a homoge-
neous blend. Finally, the physical mixture was frozen and then lyophilized in the same
way as the complex was prepared.
Differential thermal analysis (DTA)
DTA curves of LIG, HP-b-CD, LIG/HP-b-CD inclusion complex and their physical mix-
ture were measured with a DTA-60 differential thermal analyzer (Shimadzu, Japan). Each
sample (3–5 mg) was weighed and heated in an aluminum pan at a rate of 10.00 °C min–1 in a
20 to 400 °C temperature range under constant flow (30 mL min–1) of dry nitrogen.
FTIR spectroscopy
FTIR was conducted using a Nicolet 5DXC IR Spectrometer (Nicolet, USA). The dif-
fuse reflectance technique was used in the mid-IR (400–4000 cm–1) spectral region. The
procedure consisted of grinding the sample together with KBr (about 200–400 mg) into a
fine powder, placing the powder into a sampling cup, smoothing it, and compressing
the powder bed into the holder using a compression gauge. The sample was placed in
the light path and the spectrum was obtained.
Stability of the inclusion complex
LIG and LIG/HP-b-CD inclusion complexes were divided into four groups which
were stored at 4, 30 and 50 °C (in brown glass bottles) and under light (with light inten-
sity 1500 Lux, 4 °C), respectively. Comparative tests of the stability of free LIG and the
inclusion complex were run for 6 days. After a fixed period of time, the remaining LIG
in each sample was measured using HPLC analysis. Each test was repeated three times.
HPLC analysis of LIG levels from in vitro samples and biological samples
A HPLC system (Shimadzu, Japan) provided with a Shimadzu CBM 20A controller,
two Shimadzu LC 20 AD pumps including a degasser, a Shimadzu CTO 20 AC column
oven and a Prominence SPD 20A UV-deuterium detector was employed. Separation (20
mL injection volume) was carried out on a Kromasil ODS C18 column (250 mm × 4.6 mm,
5 mm particle size) and the detection wavelength was 328 nm. The mobile phases used
for the analysis consisted of acetonitrile/water (containing 10 % triethylamine) (65:35),
adjusted to pH 3.0 with glacial acetic acid, delivered at a flow rate of 1 mL min–1.
Bioavailability studies
Male SD rats weighing between 240 g and 260 g were fasted for 12 h before drug ad-
ministration. All the animals were maintained in the laboratory animal facility (22 ± 2 °C,
50 ± 5 % relative humidity, 12-h light/dark cycle). The rats were acclimated to the labo-
ratory environment for 1 week before starting the experiment. Water was freely avail-
able. All pharmacokinetic studies reported herein were submitted to the ethics commit-
tee on animal experimentation of Nantong University and all procedures were approved
by the Animal Care and Use Committee of Nantong University and the Jiangsu Province
Animal Care Ethics Committee (Approval ID: SYXK(SU)2007-0021).
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For intravenous (i.v.) administration, free LIG was suspended in 0.5 % Tween-80. In-
travenous bolus was given to rats via the tail vein at a dose of 20 mg kg–1. Blood samples
were collected and centrifuged at 0.08, 0.25, 1, 1.5, 2, 4, 8 h post-dosing. For the LIG as-
say, 900 mL hexane and 10 mL internal standard (Nimodipine, 100 mg mL–1) were added
to the 300 mL plasma sample. After centrifugation, the supernatant was withdrawn and
the solvent was evaporated under N2 gas. Dryness was dissolved with 100 mL mobile
phase, then 20 mL was subjected to HPLC analysis. For oral (p.o.) administration, the
LIG/HP-b-CD complex was redissolved in water and free LIG was suspended in 0.5 %
Tween-80 with 0.5 % CMC-Na. LIG and LIG/HP-b-CD administration were carried out
via gastric gavage at a dose of 400 and 100 mg kg–1, respectively. Blood samples were
collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dosing. The procedure of blood
sample treatment was the same as that described above. LIG pharmacokinetic parame-
ters such as the peak LIG plasma concentration (cmax), the time of maximum concentra-
tion (tmax), the elimination rate constant (Ke), the area under the curve (AUC), the
half-time (t1/2) and the mean residence time (MRT) after free LIG and LIG/HP-b-CD
dosing were determined from rat plasma profiles by the noncompartmental approach
using Kinetica 4.4 software.









where AUCp.o. and AUCi.v. are the area under the concentration-time curve after p.o. and
i.v. administration, respectively. Dosep.o. and Dosei.v. mean the dose of LIG or LIG/
HP-b-CD following p.o. and i.v. administration, respectively.
Relative bioavailability measures the bioavailability (estimated as AUC) of LIG
compared to LIG/HP-b-CD following p.o. Relative bioavailability (Frel) was calculated







(%) = ×100 (2)
AUCA and AUCB represent the area under the blood concentration-time curve of
LIG/HP-b-CD and LIG, DoseA and DoseB mean the dose of LIG/HP-b-CD complex and
LIG following p.o. administration.
RESULTS AND DISCUSSION
UV-Vis absorption spectrum of the inclusion complex
According to procedure 2.1, absorption spectra of the LIG/HP-b-CD complex, LIG
and HP-b-CD were recorded. The absorption spectra are given in Fig. 2. The obtained re-
sults showed that HP-b-CD had no absorption in the range 300–400 nm. A peak around
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328 nm was found on the absorption spectrum of LIG. Absorbance of the inclusion com-
plex was higher than that of LIG alone with a simultaneous hypsochromic shift of the
maximum to 324 nm. These changes were due to the interaction between LIG and
HP-b-CD, implying the inclusion complex formation (20).
Stoichiometry of the inclusion complex
According to Job’s method of continuous variation, a physical parameter directly re-
lated to the concentration of the complex can be measured for a set of samples with a con-
tinuously variable molar fraction of components. Maximum concentration of the complex
will be present in the sample where the molar ratio R corresponds to the complexation
stoichiometry (21). The plot observed in Fig. 3 shows the maximum at a molar fraction of
about 0.5, indicating that the stoichiometry of the LIG/HP-b-CD complex was 1:1.
DTA
It is known that when guest molecules are embedded in the cavity of CDs, their
melting, sublimating and/or boiling points generally shift to a different temperature or
disappear in the case of CD decomposition. The thermograms of LIG, HP-b-CD, physi-
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Fig. 2. UV spectra of: a) HP-b-CD, b) LIG and c) LIG/HP-b-CD complex.
Fig. 3. Job’s plot of LIG/HP-b-CD complex.
cal mixture and inclusion complex are shown in Fig. 4. The DTA results demonstrate an
endothermic peak for LIG (Fig. 4a) at 209.1 °C, which might be due to the decomposition
of LIG. The DTA curve of HP-b-CD alone (Fig. 4b) showed a very broad endothermic ef-
fect, which attained a maximum at around 49.2 °C corresponding to the dehydration
process. Besides, the base shift around 331.5 °C may result from a degradation process of
HP-b-CD. The DTA curve of the physical mixture of LIG with HP-b-CD (Fig. 4d) shows
the persistence of the endothermic phenomenon due to loss of water, characteristic of
HP-b-CD, and the endothermic peak for LIG, indicative of the drug alone. However, the
endothermic peak of LIG disappeared completely in the DTA thermogram of the inclu-
sion complex, as can be seen from Fig. 4c. This explains the amorphous solid dispersion
and the molecular encapsulation of LIG into the HP-b-CD nanocavity (22).
FTIR spectroscopy
Variations of the shape, shift and intensity of the FTIR absorption peaks of the guest
or host molecule can provide enough information for the occurrence of inclusion. FTIR
spectra of the inclusion complex and those for pure compounds as well as the physical
mixture are shown in Fig. 5. The FT-IR spectrum of LIG is characterized by principal ab-
sorption peaks at 1766 cm–1 (C=O stretching vibration); 1437, 1270 and 1051cm–1 (C-O
stretching vibrations); 960 cm–1 (C=C-H bending vibration of the unsaturated six-mem-
bered ring) and 704 cm–1 (C=C-H bending vibration of the cis-alkene). The IR spectrum
of HP-b-CD shows prominent peaks at 3422 cm–1 (O-H stretching vibrations); 2931 cm–1
(C-H stretching vibrations); 1642 cm–1 (H-O-H bending vibrations); 1038 and 1084 cm–1
(C-H, C-O stretching vibrations). It can be seen that the spectrum of the physical mixture
is essentially a combination of LIG and HP-b-CD, indicating that a physical mixture does
not lead to inclusion. However, there were obvious changes in the FTIR spectra after the
LIG/HP-b-CD complex was formed. The band at 1270 cm–1 corresponding to C-O stretch-
ing vibrations of the lactone ring disappeared in the complex. The band at 1766 cm–1
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Fig. 4. DTA thermograms of: a) LIG, b) HP-b-CD, c) LIG/HP-b-CD complex and d) physical
mixture.
corresponding to C=O stretching vibration shifted to 1752 cm–1 and the intensity de-
creased. The observed changes in the FTIR spectra of LIG complexed with HP-b-CD are
due to a restriction of the vibration of the LIG molecule upon its encapsulation into the
HP-b-CD cavity (23). Therefore, the FTIR spectroscopy result indicated that the inclusion
complex of LIG with HP-b-CD was obtained.
Stability studies
Inclusion complexation with CDs can affect the physical and chemical properties of
guest molecules and usually leads to retardation of degradation processes (24). As shown
in Fig. 6a, within 6 days under light, free LIG underwent severe degradation of 77.9 %,
whereas the LIG remaining in the inclusion complex was 77.8 %. Although the effect of
light on the inclusion complex was still significant, the stability of LIG against light was
greatly enhanced when it formed the inclusion complex with HP-b-CD.
During 6 days, degradation of free LIG occurred rapidly at 4 and 30 °C (Figs. 6b and
c) and reached the degradation percentage of 31.80 and 89.09 %, respectively. However,
the inclusion complex remained stable for 6 days at 4 and 30 °C. At 50 °C, LIG degraded
completely within 5 days. Although LIG remaining in the inclusion complex reduced
over time at 50 °C, the reduction speed was much lower than that of pure LIG. These re-
sults strongly suggest that inclusion complexation afforded an efficient protection for LIG.
Thus, the stability of LIG against elevated temperature was effectively increased through
its complexation with HP-b-CD.
Pharmacokinetics in rat plasma
The HPLC method for the determination of LIG in rat plasma has been developed
and validated over a concentration range of 20–1000 ng mL–1. The calibration curve for
LIG was prepared as y = 0.0012x – 0.0266 (R = 0.9968). The RSD of LIG for inter-day and
intra-day precision and accuracy at low, medium and high concentration (20, 200 and
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Fig. 5. FTIR spectra of: a) LIG, b) HP-b-CD, c) LIG/HP-b-CD complex and d) physical mixture.
4000 ng mL–1) was less than 11.2 %. LIG recoveries at the above mentioned concentra-
tions were 84.1, 86.2 and 93.5 %, respectively. The LOQ and LOD for LIG were 20 and 10
ng mL–1, respectively.
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Fig. 6. Stability of LIG and inclusion complex under: a) light and at temperature of b) 4, c) 30
and d) 50 °C.
Table I. Pharmacokinetic parameters of LIG administered at different doses and different preparations in rats
Pharmacokinetic
parameters
Lig(20 mg kg–1 i.v.) Lig(400 mg kg–1 p.o.)
Lig/HP-â-CD
(100 mg kg–1 p.o.)
A (ng mL–1) 2458.55 ± 782.42 2764.92 ± 1357.72 1886.86 ± 265.65
Ke(h
–1) 1.44 ± 0.35 1.17 ± 0.33 0.70 ± 0.25
Ka(h
–1) 150.47 ± 14.52 2.65 ± 0.73 4.36 ± 0.97
t1/2(h) 0.51 ± 0.15 0.62 ± 0.14 1.07 ± 0.31
MRT (h) 1.12 ± 0.16 2.11 ± 0.23 2.75 ± 0.20
cmax(ng mL
–1) 3244.26 ± 484.14 2640.55 ± 483.91 1979.57 ± 666.83
Tmax (h) 0.08 ± 0.00 0.50 ± 0.00 0.50 ± 0.00
Vc/F (mg ng–1 mL–1) 0.01 ± 0.00 0.17 ± 0.06 0.05 ± 0.01
AUCt (h ng mL
–1) 1912.35 ± 141.19 2857.98 ± 522.94 3428.95 ± 569.28
AUCi (h ng mL
–1) 1990.68 ± 110.61 2877.11 ± 518.85 3465.72 ± 573.56
AIC 40.37 ± 3.76 70.39 ± 2.77 65.01 ± 5.17
Fabs (%) 100 7.47 35.86
Each value represents the mean ± SD, n = 4.
The mean plasma concentration vs. time profiles of LIG administered at different
doses and different preparations in rats are shown in Fig. 7. The plasma drug concentra-
tion in rats after receiving an i.v. dose of 20 mg kg–1 LIG increased rapidly and with an
average maximal concentration (cmax) of 3244.26 ± 484.14 ng mL–1 and an average time to
cmax (tmax) of 0.08 ± 0.00 h. After oral administration of 400 mg kg–1 LIG and 100 mg kg–1
LIG/HP-b-CD complex, the plasma drug concentration in rats also increased rapidly
and reached a cmax of 2640.55 ± 483.91 ng mL–1 and 1979.57 ± 666.83 ng mL–1 at the same
time (0.50 ± 0.00 h).
LIG/HP-b-CD showed high plasma concentrations in rats compared to free LIG.
The absolute bioavailability (Fabs%) values of LIG in the rats treated with LIG/HP-b-CD
were significantly higher (35.9 %) than those of free LIG (7.5 %). Relative bioavailability
(Frel %) of LIG/HP-b-CD was about 530 % and there was an about 4.8-fold increase in
apparent bioavailability. It was reported that the oral bioavailability of LIG was only 2.6 %
in rats (25). The results obtained from the pharmacokinetic study of LIG after oral ad-
ministration clearly indicate that inclusion of LIG into HP-b-CD could increase both the
extent and the rate of its oral absorption. Since LIG is a promising neuroprotective agent
for preventing and treating ischemic disorders and AD, the current study reveals that
HP-b-CD may be effectively utilized for the inclusion of LIG in designing appropriate
formulations to meet clinical needs.
CONCLUSIONS
In conclusion, this study showed that LIG was capable of forming an inclusion com-
plex with HP-b-CD in the stoichiometric ratio of 1:1. The structure of the inclusion com-
plex was characterized by UV-Vis spectroscopy, DTA and FTIR spectroscopy. Stability
studies indicated that HP-b-CD can greatly improve the stability of LIG against tempe-
rature and light in the form of an inclusion complex. Further, the oral bioavailability of
LIG in rats was greatly enhanced upon its complexation with HP-b-CD. These results
strongly suggest that LIG/HP-b-CD complexation can be of great use in increasing the
stability and biological efficacy of LIG.
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Fig. 7. Mean (± SD) plasma concentration-time profiles of LIG after intravenous administration of
free LIG at a dose of 20 mg kg–1 (), oral administration of free LIG at a dose of 400 mg kg–1 () and
LIG/HP-b-CD complex at a dose of 100 mg kg–1 (), n = 4.
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